title: Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models.
abstract: The primary immune role of B cells is to produce antibodies, but they can also influence T cell function via antigen presentation and, in some contexts, immune regulation. Whether their roles in tumour immunity are similar to those in other chronic immune responses such as autoimmunity and chronic infection, where both pro- and anti-inflammatory roles have been described, remains controversial. Many studies have aimed to define the role of B cells in antitumor immune responses, but despite this considerable body of work, it is not yet possible to predict how they will affect immunity to any given tumour. In many human cancers, the presence of tumour-infiltrating B cells and tumour-reactive antibodies correlates with extended patient survival, and this clinical observation is supported by data from some animal models. On the other hand, T cell responses can be adversely affected by B cell production of immunoregulatory cytokines, a phenomenon that has been demonstrated in humans and in animal models. The isotype and concentration of tumour-reactive antibodies may also influence tumour progression. Recruitment of B cells into tumours may directly reflect the subtype and strength of the anti-tumour T cell response. As the response becomes chronic, B cells may attenuate T cell responses in an attempt to decrease host damage, similar to their described role in chronic infection and autoimmunity. Understanding how B cell responses in cancer are related to the effectiveness of the overall anti-tumour response is likely to aid in the development of new therapeutic interventions against cancer.
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Thomas V
authors.initials: TV
authors.lastname: Guy
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Alexandra M
authors.initials: AM
authors.lastname: Terry
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Holly A
authors.initials: HA
authors.lastname: Bolton
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: David G
authors.initials: DG
authors.lastname: Hancock
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Elena
authors.initials: E
authors.lastname: Shklovskaya
authors.affiliation: T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia. b.fazekas@centenary.org.au.|Discipline of Dermatology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. b.fazekas@centenary.org.au.
authors.forename: Barbara
authors.initials: B
authors.lastname: Fazekas de St. Groth
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology*
chemical_list: D000906:Antibodies
keywords: Antibodies; B cells; Clinical correlations; Tumour models